High-intensity interval training for breast cancer survivors after chemotherapy
High Intensity Interval Training: Optimizing Exercise Therapy to Mitigate Cardiovascular Disease Risk Following Breast Cancer Chemotherapy
This study tests if high-intensity interval training can help female breast cancer survivors improve their heart health after chemotherapy better than regular exercise over 12 weeks.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 158 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | Female |
| Sponsor | University of Florida Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Gainesville, Florida) |
| Trial ID | NCT05913713 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of high-intensity interval training (HIIT) on cardiovascular rehabilitation in female breast cancer survivors who have completed chemotherapy. The research aims to compare the effectiveness and sustainability of HIIT versus moderate-intensity continuous training over a 12-week intervention period. Participants will be monitored for cardiovascular health improvements and potential reductions in cardiovascular disease risk factors. The study is designed to provide insights into tailored exercise regimens for this specific patient population.
Who should consider this trial
Good fit: Ideal candidates are female breast cancer survivors aged 18 to 85 who completed chemotherapy between 6 to 18 months prior to enrollment.
Not a fit: Patients currently undergoing surgery or radiation therapy, or those with significant cardiovascular diseases, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly reduce the risk of cardiovascular disease in breast cancer survivors.
How similar studies have performed: Previous studies have shown positive outcomes with exercise interventions in cancer survivors, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * female patients based on biological sex * 18 to 85 years of age * diagnosis of primary, invasive, non-metastatic, stages I-III breast cancer * completed chemotherapy for breast cancer (anthracycline, alkylating agent and/or taxane) more than 6 months but less than 18 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy, and bisphosphonates are allowed within 6 months of study enrollment and during study participation * absence of contraindications to exercise or to participate in study * study clinician approval Exclusion Criteria: * do not meet inclusion criteria * scheduled to receive surgery or radiation therapy during the intervention period * any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent) * lymphedema stage ≥2 prior to study enrollment * are pregnant * current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)
Where this trial is running
Gainesville, Florida
- Integrative Cardiovascular Physiology Laboratory, University of Florida — Gainesville, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Demetra Christou, PhD — University of Florida
- Study coordinator: Demetra Christou, PhD
- Email: ddchristou@ufl.edu
- Phone: 352-294-1746
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.